Zim Laboratories valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
Price multiples — at each FY-end close
204.47×————
2.55×————
1.90×————
146.82×————
Enterprise multiples
2.15×————
30.27×————
110.64×————
Yield
0.5%————
0.7%————
Reference — adjusted share basis
₹141.26————
₹0.69₹1.09₹2.27₹3.22₹4.57
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹756 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————204.47
P/B————2.55
P/Sales————1.90
Price to Free Cash Flow————146.82
Enterprise Multiples
EV/Sales————2.15
EV/EBITDA————30.27
EV/EBIT————110.64
Yield
Earnings Yield %————0.49
FCF Yield %————0.68
Reference — adjusted share basis
Price (FY-end close, adj.)————141.26
EPS (adj.)4.573.222.271.090.69
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.